KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) EBITDA Margin: 2010-2025

Historic EBITDA Margin for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to 33.10%.

  • Emergent BioSolutions' EBITDA Margin rose 1115.00% to 33.10% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.02%, marking a year-over-year increase of 3055.00%. This contributed to the annual value of -10.42% for FY2024, which is 5881.00% up from last year.
  • Emergent BioSolutions' EBITDA Margin amounted to 33.10% in Q3 2025, which was up 2,815.09% from 1.14% recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' EBITDA Margin ranged from a high of 39.13% in Q4 2021 and a low of -407.00% during Q2 2024.
  • For the 3-year period, Emergent BioSolutions' EBITDA Margin averaged around -54.71%, with its median value being -4.88% (2024).
  • In the last 5 years, Emergent BioSolutions' EBITDA Margin tumbled by 32,032bps in 2024 and then surged by 40,814bps in 2025.
  • Emergent BioSolutions' EBITDA Margin (Quarterly) stood at 39.13% in 2021, then tumbled by 5,588bps to -16.75% in 2022, then soared by 91bps to -15.84% in 2023, then skyrocketed by 1,096bps to -4.88% in 2024, then surged by 1,115bps to 33.10% in 2025.
  • Its EBITDA Margin was 33.10% in Q3 2025, compared to 1.14% in Q2 2025 and 22.46% in Q1 2025.